Details of the Drug Combination

General Information of Drug Combination (ID: DCGQSU9)

Drug Combination Name
Crizotinib Rifampicin
Indication
Disease Entry Status REF
Non-Small Cell Lung Cancer ALK-positive Phase 1 [1]
Component Drugs Crizotinib   DM4F29C Rifampicin   DM5DSFZ
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Crizotinib
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Approved [2]
Crizotinib Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Modulator [8]
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Modulator [8]
Proto-oncogene c-Ros (ROS1) TTSZ6Y3 ROS1_HUMAN Modulator [8]
HGF/Met signaling pathway (HGF/Met pathway) TTKA5LP NOUNIPROTAC Inhibitor [9]
------------------------------------------------------------------------------------
Crizotinib Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Crizotinib Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [12]
------------------------------------------------------------------------------------
Crizotinib Interacts with 45 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [13]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Activity [14]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Increases Response To Substance [6]
ALK tyrosine kinase receptor (ALK) OTV3P4V8 ALK_HUMAN Decreases Response To Substance [15]
Prominin-1 (PROM1) OTBHV8NX PROM1_HUMAN Decreases Expression [5]
CD44 antigen (CD44) OT9TTJ41 CD44_HUMAN Decreases Expression [5]
Epithelial cell adhesion molecule (EPCAM) OTHBZK5X EPCAM_HUMAN Decreases Expression [5]
Cytidine deaminase (CDA) OT3HXP6N CDD_HUMAN Decreases Expression [5]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Increases Expression [16]
Acyl-CoA 6-desaturase (FADS2) OTUX531P FADS2_HUMAN Increases Expression [16]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Increases Expression [16]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [16]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [16]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [16]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Increases Expression [16]
Sterol regulatory element-binding protein 2 (SREBF2) OTBXUNPL SRBP2_HUMAN Increases Expression [16]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [16]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Increases Phosphorylation [16]
Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C) OT6KFNMS CAC1C_HUMAN Decreases Activity [16]
Sodium channel protein type 5 subunit alpha (SCN5A) OTGYZWR6 SCN5A_HUMAN Decreases Activity [16]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [6]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Expression [6]
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Decreases Secretion [17]
Lutropin subunit beta (LHB) OT5GBOVJ LSHB_HUMAN Decreases Secretion [17]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Decreases Activity [18]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [19]
Tissue factor (F3) OT3MSU3B TF_HUMAN Increases Expression [20]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Phosphorylation [19]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [21]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [22]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [22]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [23]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Phosphorylation [24]
Ras GTPase-activating-like protein IQGAP1 (IQGAP1) OTZRWTGA IQGA1_HUMAN Decreases Phosphorylation [25]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [24]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [6]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Cleavage [26]
Echinoderm microtubule-associated protein-like 4 (EML4) OTJC45TA EMAL4_HUMAN Increases Mutagenesis [22]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Decreases Activity [14]
GTPase KRas (KRAS) OT78QCN8 RASK_HUMAN Decreases Response To Substance [27]
Pro-epidermal growth factor (EGF) OTANRJ0L EGF_HUMAN Decreases Response To Substance [23]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Response To Substance [27]
Mast/stem cell growth factor receptor Kit (KIT) OTHUY3VZ KIT_HUMAN Decreases Response To Substance [15]
Proheparin-binding EGF-like growth factor (HBEGF) OTLU00JS HBEGF_HUMAN Decreases Response To Substance [23]
Protransforming growth factor alpha (TGFA) OTPD1LL9 TGFA_HUMAN Decreases Response To Substance [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 45 DOT(s)
Indication(s) of Rifampicin
Disease Entry ICD 11 Status REF
Non-insulin dependent diabetes 5A11 Approved [3]
Pulmonary tuberculosis 1B10.Z Approved [4]
Rifampicin Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [36]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [37]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [38]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Metabolism [39]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [40]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [41]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [42]
Rifampicin monooxygenase (rox) DE6PKFB ROX_NOCFA Metabolism [43]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Rifampicin Interacts with 228 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [44]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Increases Expression [45]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases Expression [46]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Expression [47]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Expression [48]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Expression [49]
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Decreases Expression [50]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Increases Expression [51]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Increases Expression [52]
Alcohol dehydrogenase 1C (ADH1C) OTO1DV7F ADH1G_HUMAN Increases Expression [49]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Expression [49]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Increases Expression [49]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Increases Expression [49]
ATP-binding cassette sub-family G member 1 (ABCG1) OT5BG6MK ABCG1_HUMAN Increases Expression [49]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Increases Expression [53]
Cytochrome P450 3A7 (CYP3A7) OTTCDHHM CP3A7_HUMAN Increases Expression [53]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Increases Expression [47]
Cytochrome P450 7A1 (CYP7A1) OT8Z5KLD CP7A1_HUMAN Decreases Expression [47]
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1) OTG2T749 CP24A_HUMAN Increases Expression [54]
Glutathione S-transferase A1 (GSTA1) OTA7K5XA GSTA1_HUMAN Increases Expression [55]
Cocaine esterase (CES2) OTC647SQ EST2_HUMAN Increases Expression [56]
Sterol 26-hydroxylase, mitochondrial (CYP27A1) OT649C01 CP27A_HUMAN Increases Expression [57]
ATP-binding cassette sub-family C member 5 (ABCC5) OT34G4US MRP5_HUMAN Increases Expression [46]
Epoxide hydrolase 1 (EPHX1) OTBKWQER HYEP_HUMAN Increases Expression [50]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [50]
Cytochrome P450 2F1 (CYP2F1) OTY3HJH1 CP2F1_HUMAN Decreases Expression [50]
Cytochrome P450 2C18 (CYP2C18) OTY687L9 CP2CI_HUMAN Decreases Expression [50]
Cytochrome P450 2A13 (CYP2A13) OTVUDLT3 CP2AD_HUMAN Decreases Expression [50]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Expression [58]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Increases Expression [58]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Increases Expression [58]
5-aminolevulinate synthase, non-specific, mitochondrial (ALAS1) OTQY6ZSF HEM1_HUMAN Increases Expression [59]
Transmembrane protein 120B (TMEM120B) OTA5XMI9 T120B_HUMAN Decreases Expression [30]
Uncharacterized protein C4orf51 (C4ORF51) OTIHD7NB CD051_HUMAN Decreases Expression [30]
Ankyrin repeat domain-containing protein 65 (ANKRD65) OTSZCFD8 ANR65_HUMAN Decreases Expression [30]
Transcription factor EC (TFEC) OTUST8MR TFEC_HUMAN Increases Expression [30]
Obscurin-like protein 1 (OBSL1) OT6M8M3J OBSL1_HUMAN Decreases Expression [30]
PC4 and SFRS1-interacting protein (PSIP1) OT4YAFUS PSIP1_HUMAN Increases Expression [30]
SUN domain-containing protein 1 (SUN1) OTIU8V4U SUN1_HUMAN Decreases Expression [30]
Integrin beta-like protein 1 (ITGBL1) OTJDHE17 ITGBL_HUMAN Decreases Expression [30]
Tissue-type plasminogen activator (PLAT) OTQPDNAB TPA_HUMAN Decreases Expression [30]
Carbonic anhydrase 1 (CA1) OTNFBVVQ CAH1_HUMAN Decreases Expression [30]
Coagulation factor XIII B chain (F13B) OTIZXROK F13B_HUMAN Increases Expression [30]
Myocardial zonula adherens protein (MYZAP) OTAZCNBT MYZAP_HUMAN Decreases Expression [30]
LIM and senescent cell antigen-like-containing domain protein 3 (LIMS3) OTTMS7V8 LIMS3_HUMAN Decreases Expression [30]
Spectrin beta chain, erythrocytic (SPTB) OT1Q9ABM SPTB1_HUMAN Increases Expression [30]
Myosin-6 (MYH6) OT3YNCH1 MYH6_HUMAN Increases Expression [30]
ETS domain-containing protein Elk-1 (ELK1) OTH9MXD6 ELK1_HUMAN Decreases Expression [30]
Galactoside alpha-(1,2)-fucosyltransferase 1 (FUT1) OTODG57A FUT1_HUMAN Decreases Expression [30]
Nuclear transcription factor Y subunit alpha (NFYA) OTWFFOVH NFYA_HUMAN Decreases Expression [30]
Paired box protein Pax-7 (PAX7) OTDMQRPO PAX7_HUMAN Decreases Expression [30]
Adenosine receptor A2a (ADORA2A) OTVRBZ0I AA2AR_HUMAN Decreases Expression [30]
Leukocyte tyrosine kinase receptor (LTK) OT4GPX7K LTK_HUMAN Increases Expression [30]
Pyruvate kinase PKLR (PKLR) OTTTM1QI KPYR_HUMAN Increases Expression [30]
Corticotropin-releasing factor receptor 1 (CRHR1) OT5PWHAI CRFR1_HUMAN Decreases Expression [30]
Nitric oxide synthase, inducible (NOS2) OTKKIOJ1 NOS2_HUMAN Increases Expression [30]
Histamine H1 receptor (HRH1) OT8F9FV6 HRH1_HUMAN Increases Expression [30]
Guanine nucleotide-binding protein G(olf) subunit alpha (GNAL) OTESDTEU GNAL_HUMAN Decreases Expression [30]
Glutamate receptor 1 (GRIA1) OT85LOCJ GRIA1_HUMAN Decreases Expression [30]
Transcriptional regulator ATRX (ATRX) OT77RSQW ATRX_HUMAN Increases Expression [30]
Dual specificity protein kinase CLK2 (CLK2) OT1CRSY2 CLK2_HUMAN Decreases Expression [30]
Type I iodothyronine deiodinase (DIO1) OTFYLYJ0 IOD1_HUMAN Increases Expression [30]
Serpin B9 (SERPINB9) OTJ811IF SPB9_HUMAN Increases Expression [30]
Neural retina-specific leucine zipper protein (NRL) OT65MFKQ NRL_HUMAN Increases Expression [30]
Aquaporin-4 (AQP4) OTA9MYD5 AQP4_HUMAN Decreases Expression [30]
High mobility group nucleosome-binding domain-containing protein 5 (HMGN5) OTUUAHVQ HMGN5_HUMAN Increases Expression [30]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Decreases Expression [30]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Decreases Expression [30]
28 kDa heat- and acid-stable phosphoprotein (PDAP1) OTJSWMOD HAP28_HUMAN Decreases Expression [30]
PCNA-associated factor (PCLAF) OTMVIOUU PAF15_HUMAN Increases Expression [30]
Toll-like receptor 1 (TLR1) OTZTQIZO TLR1_HUMAN Increases Expression [30]
Mediator of RNA polymerase II transcription subunit 1 (MED1) OTOO24C4 MED1_HUMAN Decreases Expression [30]
INO80 complex subunit D (INO80D) OTY39R4P IN80D_HUMAN Decreases Expression [30]
Arylsulfatase J (ARSJ) OTE0YXM1 ARSJ_HUMAN Decreases Expression [30]
Uncharacterized protein C9orf153 (C9ORF153) OT4GKX8W CI153_HUMAN Decreases Expression [30]
Ras-related GTP-binding protein B (RRAGB) OTY10XRU RRAGB_HUMAN Decreases Expression [30]
Olfactory receptor 4A47 (OR4A47) OTB5Y637 O4A47_HUMAN Decreases Expression [30]
NADH-cytochrome b5 reductase-like (CYB5RL) OTPPN39P NB5R5_HUMAN Increases Expression [30]
Transmembrane protein 88 (TMEM88) OTA96YEL TMM88_HUMAN Increases Expression [30]
Thrombospondin type-1 domain-containing protein 4 (THSD4) OTXDBMDC THSD4_HUMAN Increases Expression [30]
Ankyrin repeat and sterile alpha motif domain-containing protein 1B (ANKS1B) OT26DGM9 ANS1B_HUMAN Decreases Expression [30]
Exopolyphosphatase PRUNE1 (PRUNE1) OTQ3UHWQ PRUN1_HUMAN Decreases Expression [30]
General transcription factor II-I repeat domain-containing protein 2A (GTF2IRD2) OT63Q58O GTD2A_HUMAN Increases Expression [30]
Dynein regulatory complex protein 11 (IQCA1) OTFBF3FI DRC11_HUMAN Decreases Expression [30]
Kin of IRRE-like protein 3 (KIRREL3) OTW7PENS KIRR3_HUMAN Decreases Expression [30]
Kelch-like protein 23 (KLHL23) OT2UVSD2 KLH23_HUMAN Decreases Expression [30]
Transmembrane protein 145 (TMEM145) OT62OZHH TM145_HUMAN Increases Expression [30]
Ethanolamine-phosphate phospho-lyase (ETNPPL) OTSXO9P6 AT2L1_HUMAN Increases Expression [30]
Probable mitochondrial glutathione transporter SLC25A40 (SLC25A40) OTYMJ69D S2540_HUMAN Decreases Expression [30]
Protein FAM200A (FAM200A) OTB1SATW F200A_HUMAN Increases Expression [30]
Tsukushi (TSKU) OT1XMRIM TSK_HUMAN Increases Expression [30]
Septin-8 (SEPTIN8) OTSZLI64 SEPT8_HUMAN Increases Expression [30]
Homeobox protein DLX-4 (DLX4) OTLWVCN4 DLX4_HUMAN Decreases Expression [30]
H/ACA ribonucleoprotein complex non-core subunit NAF1 (NAF1) OTMJKJAK NAF1_HUMAN Decreases Expression [30]
DDB1- and CUL4-associated factor 5 (DCAF5) OTTUFC93 DCAF5_HUMAN Decreases Expression [30]
Protein TBATA (TBATA) OTGDMAAL TBATA_HUMAN Decreases Expression [30]
Nucleosome assembly protein 1-like 5 (NAP1L5) OTF4Q6ZW NP1L5_HUMAN Increases Expression [30]
Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2 (AGAP2) OTEYO9TM AGAP2_HUMAN Decreases Expression [30]
Interleukin-12 receptor subunit beta-2 (IL12RB2) OTDLV8H8 I12R2_HUMAN Decreases Expression [30]
RANBP2-like and GRIP domain-containing protein 5/6 (RGPD6) OT1KQSOB RGPD5_HUMAN Decreases Expression [30]
Tripartite motif-containing protein 51 (TRIM51) OT5Y1T5Q TRI51_HUMAN Decreases Expression [30]
Sorbin and SH3 domain-containing protein 1 (SORBS1) OTWH8762 SRBS1_HUMAN Decreases Expression [30]
R-spondin-3 (RSPO3) OTZK8GDS RSPO3_HUMAN Decreases Expression [30]
Zinc finger protein GLIS2 (GLIS2) OTOUUV1X GLIS2_HUMAN Increases Expression [30]
Paternally-expressed gene 3 protein (PEG3) OTHQW98S PEG3_HUMAN Increases Expression [30]
Serine/threonine-protein kinase SIK2 (SIK2) OTODY7XG SIK2_HUMAN Decreases Expression [30]
Forkhead box protein P1 (FOXP1) OTSG6XGF FOXP1_HUMAN Increases Expression [30]
5' exonuclease Apollo (DCLRE1B) OT2LFW7A DCR1B_HUMAN Decreases Expression [30]
Sideroflexin-1 (SFXN1) OTL66767 SFXN1_HUMAN Decreases Expression [30]
Casein kinase I isoform gamma-1 (CSNK1G1) OTCXB7BI KC1G1_HUMAN Decreases Expression [30]
Synembryn-B (RIC8B) OT90BA3B RIC8B_HUMAN Decreases Expression [30]
Phospholipase A and acyltransferase 2 (PLAAT2) OTI5RMWB PLAT2_HUMAN Decreases Expression [30]
Centlein (CNTLN) OT13NATW CNTLN_HUMAN Increases Expression [30]
Actin-related protein 10 (ACTR10) OTRF3E58 ARP10_HUMAN Increases Expression [30]
Interleukin-37 (IL37) OT4H8YRL IL37_HUMAN Increases Expression [30]
Polycystin-2-like protein 1 (PKD2L1) OT1KJDAT PK2L1_HUMAN Decreases Expression [30]
ABI gene family member 3 (ABI3) OTQTDSHP ABI3_HUMAN Decreases Expression [30]
Homologous-pairing protein 2 homolog (PSMC3IP) OT9UB5UO HOP2_HUMAN Increases Expression [30]
STE20/SPS1-related proline-alanine-rich protein kinase (STK39) OTXHT5FR STK39_HUMAN Increases Expression [30]
Paired immunoglobulin-like type 2 receptor alpha (PILRA) OTBE0PLF PILRA_HUMAN Decreases Expression [30]
Integrator complex subunit 6 (INTS6) OT6GDV46 INT6_HUMAN Decreases Expression [30]
Cip1-interacting zinc finger protein (CIZ1) OT3UKHPI CIZ1_HUMAN Decreases Expression [30]
Multiple inositol polyphosphate phosphatase 1 (MINPP1) OTNYPPCC MINP1_HUMAN Increases Expression [30]
Microtubule-associated protein RP/EB family member 3 (MAPRE3) OTSCLETV MARE3_HUMAN Increases Expression [30]
E3 ubiquitin-protein ligase RNF6 (RNF6) OTNAXM6D RNF6_HUMAN Decreases Expression [30]
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Increases Expression [60]
Hexokinase-4 (GCK) OTR3Q0NN HXK4_HUMAN Decreases Expression [61]
Matrilin-2 (MATN2) OTVDR68G MATN2_HUMAN Increases Expression [62]
Long-chain fatty acid transport protein 2 (SLC27A2) OT7JEG5F S27A2_HUMAN Increases Expression [63]
Pendrin (SLC26A4) OTXUTLVS S26A4_HUMAN Decreases Expression [63]
ABC-type organic anion transporter ABCA8 (ABCA8) OTCWLX6N ABCA8_HUMAN Decreases Expression [63]
Solute carrier organic anion transporter family member 2B1 (SLCO2B1) OTERJ4VQ SO2B1_HUMAN Increases Expression [63]
ATP-binding cassette sub-family C member 6 (ABCC6) OTZT0LKT MRP6_HUMAN Increases Expression [63]
Solute carrier family 2, facilitated glucose transporter member 2 (SLC2A2) OTBL2W7R GTR2_HUMAN Decreases Expression [63]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Increases Expression [63]
Excitatory amino acid transporter 2 (SLC1A2) OTEP3QGN EAA2_HUMAN Decreases Expression [63]
Solute carrier family 15 member 1 (SLC15A1) OT1P16B5 S15A1_HUMAN Decreases Expression [63]
Sodium- and chloride-dependent betaine transporter (SLC6A12) OTKOR4F2 S6A12_HUMAN Increases Expression [63]
Sodium- and chloride-dependent glycine transporter 1 (SLC6A9) OTHRUON2 SC6A9_HUMAN Increases Expression [63]
Sulfate transporter (SLC26A2) OTJNHNTO S26A2_HUMAN Decreases Expression [63]
Amino acid transporter heavy chain SLC3A1 (SLC3A1) OT56V01A SLC31_HUMAN Decreases Expression [63]
Sodium-dependent phosphate transporter 2 (SLC20A2) OT6E2DAX S20A2_HUMAN Decreases Expression [63]
Sodium-dependent phosphate transport protein 1 (SLC17A1) OTTZGOFB NPT1_HUMAN Decreases Expression [63]
Sodium-coupled monocarboxylate transporter 2 (SLC5A12) OTKY9NAL SC5AC_HUMAN Increases Expression [63]
Long-chain fatty acid transport protein 3 (SLC27A3) OTXB60L7 S27A3_HUMAN Decreases Expression [63]
ATP-binding cassette sub-family C member 10 (ABCC10) OT2JRWWJ MRP7_HUMAN Increases Expression [63]
Solute carrier family 23 member 3 (SLC23A3) OTK1M79V S23A3_HUMAN Decreases Expression [63]
Solute carrier family 25 member 34 (SLC25A34) OTY1YFLG S2534_HUMAN Decreases Expression [63]
Calcium/manganese antiporter SLC30A10 (SLC30A10) OTXM5JW4 ZNT10_HUMAN Decreases Expression [63]
Solute carrier organic anion transporter family member 4C1 (SLCO4C1) OTVILUUN SO4C1_HUMAN Increases Expression [63]
Monocarboxylate transporter 12 (SLC16A12) OTZ63YNA MOT12_HUMAN Decreases Expression [63]
Equilibrative nucleoside transporter 4 (SLC29A4) OTWTZXMX S29A4_HUMAN Increases Expression [63]
Lysosomal proton-coupled steroid conjugate and bile acid symporter SLC46A3 (SLC46A3) OTEMDLPS S46A3_HUMAN Increases Expression [63]
Organic solute transporter subunit alpha (SLC51A) OTDJRZ0P OSTA_HUMAN Increases Expression [63]
Organic solute transporter subunit beta (SLC51B) OT4WYPSR OSTB_HUMAN Increases Expression [63]
Organic anion transporter 7 (SLC22A9) OTO4BJCC S22A9_HUMAN Decreases Expression [63]
ATP-binding cassette sub-family F member 1 (ABCF1) OT6Q079J ABCF1_HUMAN Increases Expression [63]
Solute carrier family 2, facilitated glucose transporter member 12 (SLC2A12) OT0EDNV9 GTR12_HUMAN Increases Expression [63]
Sodium/myo-inositol cotransporter 2 (SLC5A11) OTRGCUPZ SC5AB_HUMAN Increases Expression [63]
Multidrug and toxin extrusion protein 1 (SLC47A1) OTZX0U5Q S47A1_HUMAN Increases Expression [63]
ATP-binding cassette sub-family C member 11 (ABCC11) OTVHL7OR MRP8_HUMAN Increases Expression [63]
Sodium-coupled neutral amino acid symporter 2 (SLC38A2) OTALABSK S38A2_HUMAN Decreases Expression [63]
Equilibrative nucleoside transporter 1 (SLC29A1) OTLOOZZS S29A1_HUMAN Increases Expression [63]
ATP-binding cassette sub-family A member 2 (ABCA2) OTVSYK0X ABCA2_HUMAN Increases Expression [63]
ATP-binding cassette sub-family G member 8 (ABCG8) OTIJ76XW ABCG8_HUMAN Increases Expression [63]
Mitochondrial glutamate carrier 1 (SLC25A22) OTQGVI1N GHC1_HUMAN Increases Expression [63]
ATP-binding cassette sub-family B member 6 (ABCB6) OTPGZFES ABCB6_HUMAN Increases Expression [63]
Sodium- and chloride-dependent transporter XTRP3 (SLC6A20) OTHRD4XO S6A20_HUMAN Increases Expression [63]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3) OTOM3BUH SO1B3_HUMAN Decreases Expression [63]
Solute carrier family 23 member 2 (SLC23A2) OTJ5CQMA S23A2_HUMAN Increases Expression [63]
Sodium/hydrogen exchanger 8 (SLC9A8) OTR56QTT SL9A8_HUMAN Increases Expression [63]
Long-chain fatty acid transport protein 5 (SLC27A5) OT4OK511 S27A5_HUMAN Increases Expression [63]
Aldo-keto reductase family 1 member B10 (AKR1B10) OTOA4HTH AK1BA_HUMAN Increases Expression [64]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [64]
Solute carrier family 22 member 1 (SLC22A1) OT7817I4 S22A1_HUMAN Decreases Expression [65]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [66]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [67]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Increases Expression [68]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) OTY9R6FZ ERN1_HUMAN Increases Expression [69]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Expression [70]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Expression [71]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Decreases Expression [72]
Fibroblast growth factor 19 (FGF19) OT2DVJWY FGF19_HUMAN Increases Expression [73]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [74]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Increases Secretion [75]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1) OTVVI3UI DQB1_HUMAN Affects Expression [76]
Apolipoprotein C-III (APOC3) OTW3520C APOC3_HUMAN Decreases Expression [69]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Expression [69]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [74]
Protein disulfide-isomerase (P4HB) OTTYNYPF PDIA1_HUMAN Decreases Expression [69]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [77]
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Decreases Secretion [78]
Granzyme B (GZMB) OTPPVIRS GRAB_HUMAN Increases Secretion [75]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Increases Expression [68]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [79]
POU domain, class 2, transcription factor 1 (POU2F1) OTK7ELJ0 PO2F1_HUMAN Decreases Expression [71]
HLA class I histocompatibility antigen, alpha chain G (HLA-G) OTMLK1KN HLAG_HUMAN Affects Expression [76]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [79]
Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF6) OTAFHAVI ATF6A_HUMAN Increases Expression [69]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Expression [79]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Increases Expression [80]
Interleukin-13 (IL13) OTI4YS3Y IL13_HUMAN Increases Secretion [75]
Phosphoenolpyruvate carboxykinase, cytosolic (PCK1) OTNWEJ5Y PCKGC_HUMAN Increases Expression [81]
Glucose-6-phosphatase catalytic subunit 1 (G6PC1) OTJ6FM9F G6PC1_HUMAN Decreases Expression [81]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [79]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Decreases Expression [68]
MAP kinase-activated protein kinase 2 (MAPKAPK2) OT460SBO MAPK2_HUMAN Increases Phosphorylation [82]
Cytochrome P450 2J2 (CYP2J2) OTJBTEH8 CP2J2_HUMAN Decreases Expression [83]
Microsomal triglyceride transfer protein large subunit (MTTP) OTNUVSDT MTP_HUMAN Decreases Expression [69]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Decreases Expression [68]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Increases Expression [68]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Expression [84]
Hepatic sodium/bile acid cotransporter (SLC10A1) OTUJVMCL NTCP_HUMAN Decreases Expression [71]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Decreases Expression [81]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Expression [85]
Na(+)/citrate cotransporter (SLC13A5) OTPH1TA7 S13A5_HUMAN Increases Expression [86]
Scavenger receptor class B member 1 (SCARB1) OTAE1UA1 SCRB1_HUMAN Decreases Expression [72]
V-type proton ATPase 116 kDa subunit a 1 (ATP6V0A1) OT1IK0KA VPP1_HUMAN Increases Expression [87]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Affects Expression [76]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [66]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) OTUYHB84 MLP3B_HUMAN Decreases Metabolism [84]
Serine/threonine-protein kinase Sgk2 (SGK2) OTCTVSHF SGK2_HUMAN Increases Expression [88]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Expression [79]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Expression [71]
Angiopoietin-related protein 3 (ANGPTL3) OTCD5Z9W ANGL3_HUMAN Decreases Expression [69]
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Decreases Expression [71]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Increases Expression [89]
Arylacetamide deacetylase (AADAC) OT8VACT2 AAAD_HUMAN Decreases Acetylation [90]
------------------------------------------------------------------------------------
⏷ Show the Full List of 228 DOT(s)

References

1 ClinicalTrials.gov (NCT00585195) A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4903).
3 Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Lett. 2001 Oct 26;507(2):200-4.
4 Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children. Cochrane Database Syst Rev. 2022 Sep 6;9(9):CD013359.
5 Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Des. 2013;19(5):940-50.
6 Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
7 Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal. 2012 Apr;24(4):852-8. doi: 10.1016/j.cellsig.2011.11.020. Epub 2011 Dec 8.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
9 Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907.
10 Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94.
11 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
12 Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
13 Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos. 2013 Feb;41(2):343-52.
14 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
15 Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25.
16 Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
17 Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012 Nov 1;118(21):5302-9. doi: 10.1002/cncr.27450. Epub 2012 Apr 4.
18 Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. doi: 10.1021/jm2007613. Epub 2011 Aug 18.
19 ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
20 Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
21 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
22 Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. Epub 2011 Apr 18.
23 Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 2012 Jul 1;18(13):3592-602. doi: 10.1158/1078-0432.CCR-11-2972. Epub 2012 May 2.
24 Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011 Dec;78(6):999-1005. doi: 10.1111/j.1747-0285.2011.01239.x. Epub 2011 Oct 31.
25 Tyrosine phosphorylation of the scaffold protein IQGAP1 in the MET pathway alters function. J Biol Chem. 2020 Dec 25;295(52):18105-18121. doi: 10.1074/jbc.RA120.015891. Epub 2020 Oct 21.
26 Keratinocytes apoptosis contributes to crizotinib induced-erythroderma. Toxicol Lett. 2020 Feb 1;319:102-110. doi: 10.1016/j.toxlet.2019.11.007. Epub 2019 Nov 7.
27 Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10.
28 The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem Pharmacol. 2004 Mar 1;67(5):989-1000.
29 Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. Drug Metab Dispos. 2008 Mar;36(3):604-13.
30 Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
31 Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects. Antimicrob Agents Chemother. 2014 Oct;58(10):5987-93.
32 Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor. Antimicrob Agents Chemother. 2015 Jan;59(1):96-104.
33 Effects of xenobiotics and peroxisome proliferator-activated receptor-alpha on the human UDPglucose dehydrogenase gene expression. J Biochem Mol Toxicol. 2005;19(5):279-88. doi: 10.1002/jbt.20099.
34 Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs. J Clin Immunol. 2003 Jan;23(1):11-22. doi: 10.1023/a:1021944113833.
35 Warfarin-Rifampin-Gene (WARIF-G) Interaction: A?Retrospective, Genetic, Case-Control Study. Clin Pharmacol Ther. 2023 May;113(5):1150-1159. doi: 10.1002/cpt.2871. Epub 2023 Mar 9.
36 Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol. 2010 Aug;50(8):951-9.
37 Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31.
38 Xenobiotic-metabolizing cytochromes p450 in human white adipose tissue: expression and induction. Drug Metab Dispos. 2010 Apr;38(4):679-86.
39 Protective effect of rifampicin against acute liver injury induced by carbon tetrachloride in mice. Jpn J Pharmacol. 1995 Dec;69(4):325-34.
40 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
41 Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006 Jul;80(1):75-84.
42 Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
43 Mechanism of rifampicin inactivation in Nocardia farcinica. PLoS One. 2016 Oct 5;11(10):e0162578.
44 A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica. 1999 Mar;29(3):269-79.
45 Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther. 2004 Feb;308(2):495-501.
46 Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol. 2009 Mar 1;77(5):897-909.
47 Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
48 Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. J Biochem Mol Toxicol. 2005;19(3):149-53.
49 Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
50 Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
51 Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos. 2000 Feb;28(2):186-91.
52 Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46.
53 Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
54 Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005 Jan;115(1):177-86.
55 Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol. 2006 Jul;70(1):329-39.
56 Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol Sci. 2007 Jan;95(1):13-22.
57 PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J Lipid Res. 2007 Feb;48(2):373-84.
58 Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
59 No activation of human pregnane X receptor by hyperforin-related phloroglucinols. J Pharmacol Exp Ther. 2014 Mar;348(3):393-400.
60 Transcriptional regulation of human paraoxonase 1 by PXR and GR in human hepatoma cells. Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):348-54.
61 Involvement of pregnane X receptor in the impaired glucose utilization induced by atorvastatin in hepatocytes. Biochem Pharmacol. 2016 Jan 15;100:98-111.
62 Steroid and xenobiotic receptor-mediated effects of bisphenol A on human osteoblasts. Life Sci. 2016 Jun 15;155:29-35.
63 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
64 Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Arch Toxicol. 2018 Apr;92(4):1435-1451.
65 The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for ("squelching") SRC-1 coactivator. Br J Pharmacol. 2016 May;173(10):1703-15. doi: 10.1111/bph.13472. Epub 2016 Apr 8.
66 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
67 Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos. 2003 Nov;31(11):1296-9. doi: 10.1124/dmd.31.11.1296.
68 Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol. 2002 Jan;22(1):37-47. doi: 10.1023/a:1014256603539.
69 Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
70 Transactivation of ABCG2 through a novel cis-element in the distal promoter by constitutive androstane receptor but not pregnane X receptor in human hepatocytes. Arch Biochem Biophys. 2012 Jan 15;517(2):123-30. doi: 10.1016/j.abb.2011.10.014. Epub 2011 Nov 10.
71 Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006 Oct;34(10):1756-63. doi: 10.1124/dmd.106.010033. Epub 2006 Jul 12.
72 Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I. Biochem Biophys Res Commun. 2005 Jun 17;331(4):1533-41. doi: 10.1016/j.bbrc.2005.04.071.
73 Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J Gastroenterol. 2007 Aug 21;13(31):4230-5. doi: 10.3748/wjg.v13.i31.4230.
74 Rifampin protects human lung epithelial cells against cytotoxicity induced by clinical multi and pandrug-resistant Acinetobacter baumannii. J Infect Dis. 2011 Apr 15;203(8):1110-9. doi: 10.1093/infdis/jiq159. Epub 2011 Feb 28.
75 Detection of Drug-Responsive T-Lymphocytes in a Case of Fatal Antituberculosis Drug-Related Liver Injury. Chem Res Toxicol. 2016 Nov 21;29(11):1793-1795. doi: 10.1021/acs.chemrestox.6b00393. Epub 2016 Nov 9.
76 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
77 Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos. 2002 Jan;30(1):20-6. doi: 10.1124/dmd.30.1.20.
78 Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis. Antimicrob Agents Chemother. 2014 Aug;58(8):4657-65. doi: 10.1128/AAC.02141-13. Epub 2014 Jun 2.
79 Rifampicin-induced injury in L02 cells is alleviated by 4-PBA via inhibition of the PERK-ATF4-CHOP pathway. Toxicol In Vitro. 2016 Oct;36:186-196. doi: 10.1016/j.tiv.2016.07.017. Epub 2016 Jul 26.
80 Venlafaxine induces P-glycoprotein in human Caco-2 cells. Hum Psychopharmacol. 2007 Jan;22(1):49-53. doi: 10.1002/hup.820.
81 Expression dynamics of pregnane X receptor-controlled genes in 3D primary human hepatocyte spheroids. Arch Toxicol. 2022 Jan;96(1):195-210. doi: 10.1007/s00204-021-03177-y. Epub 2021 Oct 23.
82 Pregnane X receptor PXR activates the GADD45beta gene, eliciting the p38 MAPK signal and cell migration. J Biol Chem. 2011 Feb 4;286(5):3570-8. doi: 10.1074/jbc.M110.179812. Epub 2010 Dec 2.
83 Cytochrome P450 expression, induction and activity in human induced pluripotent stem cell-derived intestinal organoids and comparison with primary human intestinal epithelial cells and Caco-2 cells. Arch Toxicol. 2021 Mar;95(3):907-922. doi: 10.1007/s00204-020-02953-6. Epub 2020 Dec 2.
84 Inhibitory effect of PXR on ammonia-induced hepatocyte autophagy via P53. Toxicol Lett. 2018 Oct 1;295:153-161. doi: 10.1016/j.toxlet.2018.06.1066. Epub 2018 Jun 14.
85 Rifampicin activates AMPK and alleviates oxidative stress in the liver as mediated with Nrf2 signaling. Chem Biol Interact. 2020 Jan 5;315:108889. doi: 10.1016/j.cbi.2019.108889. Epub 2019 Nov 1.
86 SLC13A5 is a novel transcriptional target of the pregnane X receptor and sensitizes drug-induced steatosis in human liver. Mol Pharmacol. 2015 Apr;87(4):674-82. doi: 10.1124/mol.114.097287. Epub 2015 Jan 27.
87 Rifampicin attenuates rotenone-treated microglia inflammation via improving lysosomal function. Toxicol In Vitro. 2020 Mar;63:104690. doi: 10.1016/j.tiv.2019.104690. Epub 2019 Oct 22.
88 Serum- and glucocorticoid-regulated kinase 2 determines drug-activated pregnane X receptor to induce gluconeogenesis in human liver cells. J Pharmacol Exp Ther. 2014 Jan;348(1):131-40. doi: 10.1124/jpet.113.209379. Epub 2013 Nov 7.
89 Identification of pregnane X receptor binding sites in the regulatory regions of genes involved in bile acid homeostasis. J Mol Biol. 2005 Feb 18;346(2):505-19. doi: 10.1016/j.jmb.2004.12.003. Epub 2005 Jan 5.
90 Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol. 2011 Dec 1;82(11):1747-56.